Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT05593588
PHASE2

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

Sponsor: Avni Joshi

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.

Official title: Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2023-04-12

Completion Date

2026-12

Last Updated

2026-01-06

Healthy Volunteers

No

Interventions

DRUG

Fisetin

20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States